ÂÜÀòÂÒÂ×

Cecilia joined Agios as a chief financial officer in September 2022. She has more than 20 years of financial experience within the biopharmaceutical industry, including several companies focused on rare diseases. Prior to Agios, she served as a chief financial officer at LogicBio, where she was responsible for driving the company’s financial strategy, including evaluation of financing alternatives and analysis of business development opportunities, and managing corporate financial planning, accounting, corporate communications, and investor relations. Before her role at LogicBio, Cecilia spent more than 10 years at Biogen in roles of increasing responsibility within the finance organization. Most recently, she was vice president of R&D, worldwide medical and business development finance, advising senior management on investment prioritization to support the company’s strategic goals. Previously, she served as senior director of corporate finance, where she led global long-range planning and financial assessment of business development and M&A opportunities, and as director of finance for emerging markets, global commercial strategy, and global market access. Before joining Biogen, Ms. Jones was director of international finance at Genzyme, where she held various roles of increasing responsibility within international finance. She earned a Licenciatura en Economia from Universidad de San Andres in Buenos Aires, Argentina, and an MBA from Harvard Business School.